01 Implementation of International Standards by Contract Manufacturers Contract manufacturers are a better choice than those in India and China since they adhere to international standards for quality management systems, particularly in developed nations like the U.S., EU nations, and Japan. However, regulatory adjustments in developing nations guarantee contract manufacturers' adherence. The demand for regulatory compliance is anticipated to increase demand for several consulting services, including remediation, compliance, and QMS, and consequently support the expansion of the global market for medical device outsourcing. For instance, it is anticipated that Indian GMP standards for medical equipment will be compatible with the ISO 13485 quality management system. The demand for QMS services in the nation from OEMs and contract manufacturing firms is anticipated to rise. As a result, supporting market expansion.
01 Threat of Information Loss OEMs in the medical devices market are bound to share proprietary information about their products, collaborations, and agreements while outsourcing to third-party vendors. This creates the risk of data theft or loss, which might hamper OEMs' business. Therefore, OEMs are still hesitant to adopt outsourcing as a cost reduction, which directly hampers the market's growth. There is also a threat during medical device design transfer. Medical devices are no longer relegated to clinics and hospitals. There is tremendous pressure to augment the Internet in the medical industry, which has led to the growth of wearable or portable medical devices.They are also categorized as IoT devices that use the Internet to transfer data. Therefore, they are subject to cybersecurity threats, and, as a result, the PCBs they consist of must meet severe design and development standards. Though preventing unauthorized access to medical information is tremendously important, it is not the only security threat that medical devices encounter. Almost all device design transfers to manufacturers today are performed over the Internet through email or data uploads, potentially leaking it to unauthorized access. This is expected to restrain the market growth.
01 Commercial Success of Biologics for Clinical Use Concerns regarding the use of conventional synthetic drugs have been mitigated in part by the development of biological drugs. These artificial medications have negative side effects because they are made of artificial substances that are not naturally found in the human body. Therefore, biopharmaceutical companies are implementing biological processes to create biologics that target more than 100 diseases. Biopharmaceuticals encompass vaccines, gene therapies, cell therapies, and monoclonal antibodies. The emergence of biologics enables tackling pitfalls associated with synthetic drugs/biosimilars, which drives demand for contract manufacturing services within the pharmaceutical industries. This rising demand for outsourcing services for biologics development can be attributed to the manufacturing complexity of biologics.Biopharmaceutical manufacturing processes are sensitive and intricate in addition to being complex. A slight change in any of the factors, such as temperature, is likely to impact the safety and efficacy of the final product. These factors are expected to contribute to the growth of contract manufacturing services for biologics production. In July 2020, GSK received FDA approval for its new Nucala formulation for treating adult and pediatric patients suffering from Hypereosinophilic Syndrome (HES). With this approval, Nucala became the first targeted biologic treatment approved for patients with this eosinophil-driven disease in the US.In 2020, 53 new molecular entities and novel therapeutic biologics were approved by the FDA's Center for Drug Evaluation and Research (CDER). In 2015, 48 biotech drugs or biologics were approved by CDER. These approvals exhibit the success of biologics and biosimilars. This success is expected to accelerate the growth of the contract manufacturing and contract research services market during the forecast period. The need for higher potency, a new dose form, and biologic fill/finish by biologic manufacturers is anticipated to boost the adoption of contract services in the near future.
June 2026 PCI Pharma Services acquired Ajinomoto Althea, expanding its sterile fill-finish manufacturing, aseptic drug product development, and advanced injectable manufacturing capabilities for biopharmaceutical customers.
May 2026 Catalent expanded commercial-scale biologics manufacturing capacity by investing in advanced production technologies and digital manufacturing capabilities to support growing demand for outsourced pharmaceutical manufacturing services.
February 2026 Recipharm expanded its injectable manufacturing operations by adding new aseptic filling lines and analytical laboratories to strengthen contract development and manufacturing services for global pharmaceutical companies.
October 2025 Lonza expanded its commercial manufacturing network with additional biologics production capacity and integrated analytical testing laboratories to support end-to-end contract manufacturing services.
June 2025 Samsung Biologics expanded its global CDMO portfolio with additional manufacturing capacity and digital process technologies for biologics production.